Veracyte, Inc. (VCYT) Reaches $7.71 After 7.00% Up Move; 6 Analysts Covering Curis, Inc. (CRIS)

May 24, 2018 - By Nellie Frank

Curis, Inc. (NASDAQ:CRIS) Logo

The stock of Veracyte, Inc. (NASDAQ:VCYT) is a huge mover today! The stock increased 1.72% or $0.13 during the last trading session, reaching $7.71. About 85,437 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has declined 39.30% since May 24, 2017 and is downtrending. It has underperformed by 50.85% the S&P500.The move comes after 5 months positive chart setup for the $264.81 million company. It was reported on May, 24 by Barchart.com. We have $8.25 PT which if reached, will make NASDAQ:VCYT worth $18.54M more.

Among 7 analysts covering Curis (NASDAQ:CRIS), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. Curis had 9 analyst reports since August 10, 2015 according to SRatingsIntel. FBR Capital initiated Curis, Inc. (NASDAQ:CRIS) rating on Tuesday, August 11. FBR Capital has “Outperform” rating and $6 target. Zacks downgraded the stock to “Sell” rating in Monday, September 21 report. Guggenheim initiated Curis, Inc. (NASDAQ:CRIS) rating on Monday, October 23. Guggenheim has “Buy” rating and $7.0 target. The stock has “Buy” rating by TH Capital on Monday, November 9. As per Monday, November 9, the company rating was maintained by Roth Capital. Zacks downgraded the shares of CRIS in report on Tuesday, September 1 to “Hold” rating. Robert W. Baird maintained the shares of CRIS in report on Monday, May 7 with “Outperform” rating. See Curis, Inc. (NASDAQ:CRIS) latest ratings:

07/05/2018 Broker: Robert W. Baird Old Rating: Outperform New Rating: Outperform Old Target: $6 New Target: $3 Maintain
06/12/2017 Broker: Cowen & Co Rating: Buy

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $72.08 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

The stock decreased 4.52% or $0.0206 during the last trading session, reaching $0.4352. About 1.04M shares traded. Curis, Inc. (NASDAQ:CRIS) has declined 76.80% since May 24, 2017 and is downtrending. It has underperformed by 88.35% the S&P500.

Investors sentiment increased to 1.59 in Q4 2017. Its up 0.11, from 1.48 in 2017Q3. It improved, as 6 investors sold Curis, Inc. shares while 21 reduced holdings. 14 funds opened positions while 29 raised stakes. 75.55 million shares or 1.01% less from 76.32 million shares in 2017Q3 were reported. Bb&T Secs Ltd Limited Liability Company has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 96,522 shares. Strs Ohio accumulated 48,500 shares or 0% of the stock. Aqr Mngmt Ltd Liability has invested 0% in Curis, Inc. (NASDAQ:CRIS). Proshare Advisors Lc has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 107,976 shares. First Republic Management has invested 0% in Curis, Inc. (NASDAQ:CRIS). Principal Fin Group reported 0% stake. Bain Public Equity Mgmt Lc stated it has 633,621 shares or 0.03% of all its holdings. Thrivent Financial For Lutherans accumulated 153,708 shares. Moreover, Prelude Cap Lc has 0% invested in Curis, Inc. (NASDAQ:CRIS). 98,444 are held by Virtu Financial Limited. Parallax Volatility Advisers L P reported 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Barclays Public Limited Com accumulated 0% or 35,078 shares. Citigroup invested in 18,558 shares. Renaissance Techs Limited Liability Corporation invested in 0% or 1.33M shares. Perceptive Advisors Limited Liability Company has 951,201 shares for 0.02% of their portfolio.

Among 6 analysts covering Veracyte (NASDAQ:VCYT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Veracyte had 12 analyst reports since August 14, 2015 according to SRatingsIntel. Piper Jaffray maintained Veracyte, Inc. (NASDAQ:VCYT) on Wednesday, April 18 with “Hold” rating. Piper Jaffray maintained the stock with “Overweight” rating in Friday, August 14 report. The firm earned “Buy” rating on Friday, August 14 by BTIG Research. The rating was upgraded by Janney Capital on Tuesday, November 29 to “Buy”. The rating was initiated by Cantor Fitzgerald with “Buy” on Friday, December 18. Piper Jaffray downgraded the stock to “Hold” rating in Tuesday, November 7 report. On Tuesday, November 7 the stock rating was maintained by Leerink Swann with “Outperform”. The stock has “Neutral” rating by Janney Capital on Tuesday, November 7.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $264.81 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

More notable recent Veracyte, Inc. (NASDAQ:VCYT) news were published by: Streetinsider.com which released: “Veracyte (VCYT) Says New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly …” on May 23, 2018, also Seekingalpha.com with their article: “Veracyte, Inc. 2018 Q1 – Results – Earnings Call Slides” published on May 02, 2018, Benzinga.com published: “38 Biggest Movers From Yesterday” on May 23, 2018. More interesting news about Veracyte, Inc. (NASDAQ:VCYT) were released by: Businesswire.com and their article: “Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce …” published on May 23, 2018 as well as Seekingalpha.com‘s news article titled: “Veracyte’s (VCYT) CEO Bonnie Anderson on Q1 2018 Results – Earnings Call Transcript” with publication date: May 02, 2018.

Investors sentiment decreased to 1.23 in Q4 2017. Its down 0.53, from 1.76 in 2017Q3. It fall, as 15 investors sold Veracyte, Inc. shares while 16 reduced holdings. 12 funds opened positions while 26 raised stakes. 21.45 million shares or 4.52% less from 22.46 million shares in 2017Q3 were reported. Meeder Asset Mngmt reported 0% stake. Pdt Ltd Limited Liability Company holds 0.01% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT) for 48,570 shares. State Street Corporation invested in 331,572 shares. Renaissance Tech Ltd Llc accumulated 549,300 shares or 0% of the stock. Citigroup has invested 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Boston Advisors Limited Com stated it has 60,800 shares or 0.01% of all its holdings. Bancorp Of America Corp De reported 0% in Veracyte, Inc. (NASDAQ:VCYT). Morgan Stanley owns 164,565 shares. Art Advsrs Ltd Liability Co invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Vanguard Group has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Essex Investment Management Ltd Co reported 0.22% in Veracyte, Inc. (NASDAQ:VCYT). Barclays Public Ltd Co has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Bridgeway Mngmt holds 0.03% or 356,800 shares. Wyoming-based Cannell Limited Liability has invested 3.63% in Veracyte, Inc. (NASDAQ:VCYT). 166,876 are owned by Schwab Charles Investment Management Inc.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>